These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 18620336)

  • 21. Tuning the engine of cognition: a focus on NMDA/D1 receptor interactions in prefrontal cortex.
    Castner SA; Williams GV
    Brain Cogn; 2007 Mar; 63(2):94-122. PubMed ID: 17204357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From vice to virtue: insights from sensitization in the nonhuman primate.
    Castner SA; Williams GV
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Nov; 31(8):1572-92. PubMed ID: 17904719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Neurodevelopment and schizophrenia].
    De Erausquin GA
    Vertex; 2002; 13(49):189-97. PubMed ID: 12404020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toward a prefrontal microcircuit model for cognitive deficits in schizophrenia.
    Wang XJ
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S80-7. PubMed ID: 16508903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The dopamine system and the pathophysiology of schizophrenia: a basic science perspective.
    Goto Y; Grace AA
    Int Rev Neurobiol; 2007; 78():41-68. PubMed ID: 17349857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stimulation by neurotensin of dopamine and 5-hydroxytryptamine (5-HT) release from rat prefrontal cortex: possible role of NTR1 receptors in neuropsychiatric disorders.
    Petkova-Kirova P; Rakovska A; Zaekova G; Ballini C; Corte LD; Radomirov R; Vágvölgyi A
    Neurochem Int; 2008 Dec; 53(6-8):355-61. PubMed ID: 18835308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased proportion of high-affinity dopamine D2 receptors in rats with excitotoxic damage of the entorhinal cortex, an animal model of schizophrenia.
    Sumiyoshi T; Seeman P; Uehara T; Itoh H; Tsunoda M; Kurachi M
    Brain Res Mol Brain Res; 2005 Oct; 140(1-2):116-9. PubMed ID: 16054726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Neural mechanism underlying autistic savant and acquired savant syndrome].
    Takahata K; Kato M
    Brain Nerve; 2008 Jul; 60(7):861-9. PubMed ID: 18646626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genes, brain development and psychiatric phenotypes in velo-cardio-facial syndrome.
    Gothelf D; Schaer M; Eliez S
    Dev Disabil Res Rev; 2008; 14(1):59-68. PubMed ID: 18636637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Schizophrenia as a dynamical disease.
    an der Heiden U
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S36-42. PubMed ID: 16508894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes.
    Perlman WR; Weickert CS; Akil M; Kleinman JE
    J Psychiatry Neurosci; 2004 Jul; 29(4):287-93. PubMed ID: 15309045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changes in cortical dopamine D1 receptor binding associated with cognitive training.
    McNab F; Varrone A; Farde L; Jucaite A; Bystritsky P; Forssberg H; Klingberg T
    Science; 2009 Feb; 323(5915):800-2. PubMed ID: 19197069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia.
    Ohara K
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):469-74. PubMed ID: 17184889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dopamine-glutamate abnormalities in the frontal cortex associated with the catechol-O-methyltransferase (COMT) in schizophrenia.
    Brisch R; Bernstein HG; Krell D; Dobrowolny H; Bielau H; Steiner J; Gos T; Funke S; Stauch R; Knüppel S; Bogerts B
    Brain Res; 2009 May; 1269():166-75. PubMed ID: 19268435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neural circuits subserving behavioral flexibility and their relevance to schizophrenia.
    Floresco SB; Zhang Y; Enomoto T
    Behav Brain Res; 2009 Dec; 204(2):396-409. PubMed ID: 19110006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs.
    Apud JA; Weinberger DR
    NeuroRx; 2006 Jan; 3(1):106-16. PubMed ID: 16490417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasticity of the primate prefrontal cortex.
    Kuboshima-Amemori S; Sawaguchi T
    Neuroscientist; 2007 Jun; 13(3):229-40. PubMed ID: 17519366
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
    Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
    Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Age-related spatial working memory impairment is caused by prefrontal cortical dopaminergic dysfunction in rats.
    Mizoguchi K; Shoji H; Tanaka Y; Maruyama W; Tabira T
    Neuroscience; 2009 Sep; 162(4):1192-201. PubMed ID: 19463906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between sigma-1 receptor gene polymorphism and prefrontal hemodynamic response induced by cognitive activation in schizophrenia.
    Takizawa R; Hashimoto K; Tochigi M; Kawakubo Y; Marumo K; Sasaki T; Fukuda M; Kasai K
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):491-8. PubMed ID: 19439245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.